ClinicalTrials.gg
CompletedNCT07708831CBP276SADMADUpdated Oct 16, 2026

Trial on Single/Multiple Ascending Doses for Safety, PK and PD for CBP-0276 in Healthy Subjects

A Phase 1 interventional study of CBP-0276 Acetate and Placebo for CBP-0276 Acetate in Healthy Volunteers, sponsored by Clarent Biopharma, Inc.. Completed at 2 sites in Mexico. Open to participants aged 19 Years to 63 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Clarent Biopharma, Inc. · Phase 1, Interventional, and Treatment

Updated Oct 16, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
19 Years to 63 Years
Sex
All
01

Study summary

A double-blind, randomized, placebo-controlled, single and multiple ascending dose study with food effect to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-0276. Incidence of potential related adverse events and laboratory abnormalities produced after investigational product vs. placebo administration will be identified and analyzed. 64 subjects in total, 32 subjects in Part 1 (Single Dose Ascending:SAD) and 32 subjects in Part 2 (Multiple Dose Ascending:MAD). Healthy voluntieers (male and women), ≥ 18 to ≤ 64 years with at least least 50% of the population ≥ 45 years old will be included after sign of informed consent. Full sample in SAD and MAD will be divided in 4 subcohorts each. Subcohorts will receive 100mgQD of CBP-0276 or placebo (6:2), 200mgQD of CBP-0276 or placebo (6:2), 200mgBID of CBP-0276 or placebo (6:2) or 400mg QD of CBP-0276 or placebo (6:2). On MAD subjects will receive CBP-0276 during 14 days. The total duration of study participation for each subject (from the screening visit to the end-of-study visit) on SAD will be approximately 36 days for cohorts S1, S3, and S4 and approximately 43 days for cohort S2. The total duration of study participation for each subject (from the screening visit to the end-of-study visit) on MAD will be approximately 49 days for the M1, M2, M3, and M4 cohorts. After CBP-0276 administration plasma samples will be obtained to evaluate PK parameteres (AUC0-∞, AUC0-24, AUC0-tlast, AUC0-τ, %AUCextrap, Cmax, Ctrough, tlag, tmax.ss, t1/2, λz, MRT0-∞, CL/F, Vz/F, %Fluctuation, ARABC and ARCmax in plasma).

Read the detailed description

Phase I, double-blind, randomized, placebo-controlled clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of CBP-0276 in healthy male and female subjects. The study is divided into two parts: Part 1, a Single Ascending Dose (SAD) study, and Part 2, a Multiple Ascending Dose (MAD) study.

The trial intends to evaluate the safety and tolerability of single and multiple doses of CBP-0276, with primary outcomes including the incidence and severity of adverse events, as well as alterations in lab results, vital signs, and ECG readings. The secondary objectives are to evaluate the pharmacokinetics of CLT-0276, its linearity, and the effect of food on the drug's pharmacokinetics. Exploratory objectives include assessing scores from some neurological tests and different clinical biomarkers.

64 healthy subjects (32 in Part 1 and 32 in Part 2), aged 18 to 64 years, with at least 50% being 45 years or older will be included. Key inclusion criteria include being clinically healthy with a BMI between 18.5 and 30.0 kg/m2. Exclusion criteria are strict and include a history of significant diseases, clinically abnormal lab or ECG results, recent use of medications or illegal drugs, and a history of substance abuse.

The study will take place in two research centers in Mexico. The investigational product, CBP-0276, will be administered orally in capsule form. Doses will range from 100 mg to 400 mg, single dose. Part 1 includes four cohorts (S1-S4) where subjects will receive either a single dose of CBP-0276 or a placebo, with one cohort (S2) dedicated to assessing the food effect. Part 2 consists of four cohorts (M1-M4) with multiple doses to evaluate steady-state pharmacokinetics.

Informed Consent will be obtained prior to any study procedures, and information will be kept confidential. Adverse events will be monitored, classified by severity (mild, moderate, or severe), and assessed for causality. Any protocol deviations must be documented and reported to the Sponsor and the Institutional Ethics Committee (IEC). The protocol also specifies procedures for handling pregnancies, with the Principal Investigator required to report any occurrences to the Sponsor and the appropriate regulatory bodies.

Safety Monitoring Committee (SMC), an independent, multidisciplinary group, will oversee the safety of the subjects and advise on whether the study should continue, be modified, or be terminated.

For the safety objective, the incidences of adverse events, alterations in laboratory tests, and alterations in the subjects' 12-lead ECG will be estimated by treatment cohort and total. Adverse events, laboratory abnormalities, and 12-lead ECG abnormalities will be defined according to MedDRA and summarized through frequency tables for each treatment cohort and total by system and preferred system term. The frequency tables will be presented in full and by level of severity. Tolerability will be measured through two times before the occurrence of the first adverse event, laboratory abnormality, or 12-lead ECG abnormality and Event duration time and analyzed through survival analyses; and will be compared between the cohorts through the Kaplan Meier model.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Single Ascendent Dose
  • Multiple Ascendent Dose
  • RCT Phase 1
  • CBP-0276
03

In context

Lead sponsor

Clarent Biopharma, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 63 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinically healthy subject (male and female) aged ≥ 18 to ≤ 64 years. At least 50% of the population ≥ 45 years old.
  2. Be able and willing to read, understand, sign, and date the Form prior to entering the study.
  3. Be in good health at the discretion of the Principal Investigator, as determined by the results of a complete medical history by the physicians at the research site and laboratory tests performed by a certified Clinical Laboratory; Subjects with pre-existing medical conditions must be monitored and on stable doses of medication for a minimum period of 3 months at the screening visit.
  4. Woman of with negative serum pregnancy test at screening visit.
  5. Female with any of the following criteria:

    1. , defined by cessation of menstruation for at least 12 consecutive months and confirmed by serum FSH levels > 40 mIU/mL and estradiol \< 20 pg/mL at the screening visit or surgically sterile (with hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) and not undergoing in vitro fertilization or other fertility treatments.
    2. Use 2 methods of (one primary or highly effective and one secondary) within 90 days prior to the screening visit and up to at least 90 days after the end-of-study visit.
  6. Men must either agree to use contraception as described in the "Contraception and Pregnancy Testing" section, or remain abstinent (when it is the subject's usual and preferred lifestyle). They must also agree not to donate sperm for the duration of the study and until at least 90 days after the end-of-study visit.
  7. from ≥ 18.5 to \< 30.0 kg/m2 according to the Quetelet index at the screening visit.
  8. Non-smoker or former smoker, who has not used nicotine-containing products in any form, including nicotine patches or e-cigarettes, for 90 days prior to the Day 1 dose (first period, when applicable) and who has a negative urine cotinine test at the screening visit.
  9. Be willing to comply with all scheduled visits, treatment plan, lab tests, lifestyle considerations, restrictions, and other study procedures.

Exclusion criteria

Exclusion Criteria:

Medical history

  1. Pregnant or breastfeeding women.
  2. History of cardiac, endocrine, gastrointestinal, hematological, hepatic, immunological, metabolic, urological, pulmonary, neurological, dermatological, psychiatric or renal disease or comorbidity of importance at the discretion of the Principal Investigator (or his/her delegate).
  3. History of allergic reactions, anaphylactic reactions, severe systemic , or any allergic reaction that, in the opinion of the Principal Investigator or his/her delegate, is likely to be exacerbated by the product.
  4. History of malignant or ongoing disease, including solid tumors and hematologic (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely removed and are considered cured at least 1 year before day 1 [first period, when applicable]).
  5. Systolic blood pressure in the supine position \< 90 mmHg, >140 (18 to 59 years) or >160 (≥ 60 years); diastolic blood pressure > 90 or \< 50 mmHg, heart rate >100 or \< 40 beats per minute. Orthostatic decrease in systolic blood pressure >20 mmHg, orthostatic decrease in diastolic blood pressure >10 mmHg, or orthostatic increase in heart rate > 30 beats per minute. If any of the parameters are out of range, the measurements should be repeated two more times. Subjects will be excluded if the average of the 3 measurements is outside the corresponding reference range.
  6. Clinically significant abnormalities (at the discretion of the Principal Investigator or his/her delegate) in the 12-lead . corrected using Fridericia's correction method, QTcF > 450 ms for men and > 470 ms for women.
  7. Elective procedures or surgeries scheduled after signing the Form and until the end-of-study visit.
  8. History of gastric bypass/bariatric surgery or other gastrointestinal surgery that may affect gastric emptying or absorption of RAP-103 (excluding uncomplicated appendectomy and hernia repair performed at least 90 days prior to the screening visit).
  9. History of esophagitis and Barrett's esophagus.
  10. History of cholecystectomy.
  11. Use of pancreatic enzyme replacement within 30 days prior to the screening visit.

Risk of infection

  1. History of or positive result in the HIV detection test (HIV 1-2 antibodies).
  2. History of infection or positive result in the detection test for antibodies against the hepatitis C virus (HCVAb).
  3. Current infection (defined as positive for HepBsAg and/or HepBcAb). Subjects with immunity to hepatitis B from prior natural infection (defined as HepBsAg negative, HepBcAb positive, and HepBsAb positive) or vaccination (defined as HepBsAg negative, HepBcAb negative, and HepBsAb positive) are eligible to participate in the study.
  4. Presence of chronic, recurrent, or severe infection (e.g., pneumonia, sepsis) at the discretion of the Principal Investigator, within 90 days prior to the screening visit and between the screening visit and day -1 (of the first period, when applicable).
  5. Presence of symptoms of bacterial, fungal or viral infection (including upper respiratory tract infection) within 14 days prior to the screening visit and between screening and day -1 (of the first period, when applicable). Subjects with local fungal infection (e.g., candidiasis, ringworm, tinea pedis) are eligible for reevaluation after successful treatment of the infection.
  6. Symptoms consistent with SARS-CoV-2 infection, at the discretion of the Principal Investigator or his/her delegate, within 14 days prior to day -1 (of the first period, when applicable), including, but not limited to: temperature >37.5 °C, sore throat, new and persistent cough, shortness of breath, diarrhea, muscle pain, or loss of taste or smell.
  7. Positive COVID-19 (SARS-CoV-2) test at the screening visit.
  8. Any immunization or vaccine administered within 30 days prior to day 1 (of the first period, when applicable).

Lab Results

1. Abnormal and clinically significant results at the discretion of the Principal Investigator or his/her delegate and Sponsor, in the laboratory tests of the screening visit. Values out of range and determined to be not clinically significant at the discretion of the Principal Investigator or his/her delegate may be repeated on one occasion, the subject may be enrolled if the repeated value is within the normal range.

Pre-medicated and concomitant medications

  1. Participation in any other investigational study with drugs, biologics, medical devices, or treatment with an investigational product or therapy approved for investigational use within the previous 3 months or 7 half-lives, whichever is greater, at day -1.
  2. Prior exposure to study treatment or prior participation in studies with CBP-0276
  3. Use of any prescription or over-the-counter medication (except acetaminophen ≤ 2 g daily, aspirin ≤ 325 mg daily, ibuprofen ≤ 600 mg, and hormonal ) within 14 days prior to day -1; and unwillingness or inability to refrain from use during study participation.

Other

  1. History of alcohol or illegal drug abuse, positive urine drug test result at screening visit, positive urine drug test result, and/or positive breath alcohol test result on Day -1 (first period, when applicable), or use of illegal/recreational drugs during the development of the study.
  2. Habitual alcohol consumption > 14 drinks per week for men and > 7 drinks for women. One drink is equal to 12 ounces (360 mL) of beer, 1.5 ounces (45 mL) of hard liquor, or 5 ounces (150 mL) of wine.
  3. History or evidence of habitual use of tobacco or nicotine-containing products within 90 days prior to the Day 1 dose (first period, when applicable) and unwillingness to abstain from their use during study participation.
  4. Abnormal score on the C-SSRS and/or at the screening visit.
  5. Receipt of blood products within 2 months prior to the screening visit.
  6. Blood donation 3 months prior to the screening visit, plasma 2 weeks prior to the screening visit and 6 weeks prior to the screening visit.
  7. Strenuous physical exercise (e.g., heavy lifting, weight training, calisthenics, and aerobic exercise) within 7 days prior to Day -1 (of the first period, when applicable). Walking at a normal pace is allowed.
  8. Unwillingness or inability to comply with the requirements of the protocol.
  9. Other unspecified reasons that, at the discretion of the Principal Investigator or the Sponsor, determine that the subject is not suitable for inclusion.
  10. Subjects who had been hospitalized in the 7 months prior to the screening visit.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    SAD 1

    SAD 1 (6 on active 100mg CBP-0276 single dose and 2 on placebo)

    Drug: CBP-0276 Acetate · Drug: Placebo for CBP-0276 Acetate

  • Experimental
    SAD 2

    SAD 2 (6 on active 200mg CBP-0276 single dose and 2 on placebo)

    Drug: CBP-0276 Acetate · Drug: Placebo for CBP-0276 Acetate

  • Experimental
    SAD 3

    SAD 3 (6 on active 200mg CBP-0276 BID and 2 on placebo)

    Drug: CBP-0276 Acetate · Drug: Placebo for CBP-0276 Acetate

  • Experimental
    SAD 4

    SAD 4 (6 on active 400mg CBP-0276 single dose and 2 on placebo)

    Drug: CBP-0276 Acetate · Drug: Placebo for CBP-0276 Acetate

  • Experimental
    MAD 1

    MAD 1 (6 on active 100mg CBP-0276 one dose a day for 14 days and 2 on placebo)

    Drug: CBP-0276 Acetate · Drug: Placebo for CBP-0276 Acetate

  • Experimental
    MAD 2

    MAD 2 (6 on active 200mg CBP-0276 one dose a day for 14 days and 2 on placebo)

    Drug: CBP-0276 Acetate · Drug: Placebo for CBP-0276 Acetate

  • Experimental
    MAD 3

    MAD 3 (6 on active 200mg CBP-0276 BID for 14 days and 2 on placebo)

    Drug: CBP-0276 Acetate · Drug: Placebo for CBP-0276 Acetate

  • Experimental
    MAD 4

    MAD 4 (6 on active 400mg CBP-0276 one dose a day for 14 days and 2 on placebo)

    Drug: CBP-0276 Acetate · Drug: Placebo for CBP-0276 Acetate

Interventions

  • CBP-0276 Acetate

    Also known as: Active

  • DrugPlacebo for CBP-0276 Acetate

    Placebo for CBP-0276 Acetate: 100 mg of microcrystalline cellulose microcrystals (MCC)

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Incidence of adverse events

    Time frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD

  2. Severity of adverse events

    Severity of adverse events evaluated according MEDRA

    Time frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD

  3. Alterations systolic blood pressure

    Evaluation of systolic blood presure. Minimal valure must be 100 mm Hg and maximum 140mm HG

    Time frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD

  4. Time until first adverse event

    The length of time until the first adverse event

    Time frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD

  5. Duration of adverse events.

    The length of time for Duration of adverse events.

    Time frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD

  6. Duration of the QRT interval in electrocardiogram

    Incidence of alterations in the 12-lead electrocardiogram.

    Time frame: evalution o QRT by electro36 hours after randomization for SAD and 15 days after randomization for for MAD

Secondary outcomes

  1. Area under the curve 0 to infinity

    Area under the concentration curve in time from moment 0 to infinity

    Time frame: evaaluation o QRT intervlo by electrocardiogram24h and at day 7 post randomization for SAD and during 15 days for MAD

  2. Area under the curve 0-24H (AUc)

    Area under the concentration curve in time from time 0 to 24 hours

    Time frame: Auc analyzed by plasma lvel at24 days and day 7 after randomization for SAD and 15 days for MAD

  3. Area under curve 0 to last quantifiable concentration (AUc o-LQC)

    Area under the concentration curve in time from time 0 to the last quantifiable concentration

    Time frame: Auc0-lqc analyzed by plasma lvel at24h and day 7 after randomization for SAD and 15 days for MAD

  4. Area under curve over time during administration interval(A°UC 0-dai)|

    Area under the concentration curve over time during an administration interval

    Time frame: Aucd0-sDAI analyzed by plasma lvel at24h and day 7 after randomization for SAD and 15 days for MAD

  5. Area under curve extrapolated(AUCext

    Area under curve extrapolated

    Time frame: Aucext analyzed by plasma lvel at24h and day 7 after randomization for SAD and 15 days for MAD

  6. Peak plasma concentration (ppc)

    Peak plasma concentration after CBP-0276 Adimistration

    Time frame: ppc tsken by plasma levels o RAP103 at24h and day 7 after randomization for SAD and 15 days for MAD

  7. Concentration at end of dosing range<<(cEDR9

    Concentration measured at the end of the dosing range

    Time frame: cedr taken by plasma levels o RAP103 at24h and day 7 after randomization for SAD and 15 days for MAD

07

Study locations

2 sites
  • Centro de Investigación Clínica y Medicina Traslacional (CiMeT)
    Guadalajara, Jalisco 44340, Mexico
  • Innovacion y Desarrollo en Ciencias de la Salud (IDeCSa)
    Mexico City, 14090, Mexico
08

References and documents

Individual participant data

Plan to share: Yes — Non sensitive clinical, biomarkers and some PK parameters will be allocated on a public data base repository. Any atempt to evaluate the DB must be advise to responsible

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: June 2026 available for one year

Access criteria: Use of non sensitive data

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Feb 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Jul 16, 2026
StartActual
Sep 4, 2025
Primary completionActual
Feb 16, 2026
CompletionActual
Apr 30, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameDuration of the QRT interval in electrocardiogram36 hours after randomization for SAD and 15 days after randomization for for MAD → evalution o QRT by electro36 hours after randomization for SAD and 15 days after randomization for for MAD
Oct 16, 2026
Secondary outcomes
6 edited, 1 time frame changed
What changed in the outcomes
  • EditedArea under the curve 0-24H (AUc)Time frame: 24 days and day 7 after randomization for SAD and 15 days for MAD → Auc analyzed by plasma lvel at24 days and day 7 after randomization for SAD and 15 days for MAD
  • EditedArea under curve 0 to last quantifiable concentration (AUc o-LQC)Time frame: 24h and day 7 after randomization for SAD and 15 days for MAD → Auc0-lqc analyzed by plasma lvel at24h and day 7 after randomization for SAD and 15 days for MAD
  • EditedArea under curve over time during administration interval(A°UC 0-dai)|Time frame: 24h and day 7 after randomization for SAD and 15 days for MAD → Aucd0-sDAI analyzed by plasma lvel at24h and day 7 after randomization for SAD and 15 days for MAD
  • EditedArea under curve extrapolated(AUCextTime frame: 24h and day 7 after randomization for SAD and 15 days for MAD → Aucext analyzed by plasma lvel at24h and day 7 after randomization for SAD and 15 days for MAD
  • EditedPeak plasma concentration (ppc)Time frame: 24h and day 7 after randomization for SAD and 15 days for MAD → ppc tsken by plasma levels o RAP103 at24h and day 7 after randomization for SAD and 15 days for MAD
  • EditedConcentration at end of dosing range<<(cEDR9Time frame: 24h and day 7 after randomization for SAD and 15 days for MAD → cedr taken by plasma levels o RAP103 at24h and day 7 after randomization for SAD and 15 days for MAD
  • Time frameArea under the curve 0 to infinity24h and at day 7 post randomization for SAD and during 15 days for MAD → evaaluation o QRT intervlo by electrocardiogram24h and at day 7 post randomization for SAD and during 15 days for MAD
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameDuration of the QRT interval in electrocardiogram36 hours after randomization for SAD and 15 days after randomization for for MAD → evalution o QRT by electro36 hours after randomization for SAD and 15 days after randomization for for MAD
    Secondary outcomes 6 edited, 1 time frame changed
    What changed in the outcomes
    • EditedArea under the curve 0-24H (AUc)Time frame: 24 days and day 7 after randomization for SAD and 15 days for MAD → Auc analyzed by plasma lvel at24 days and day 7 after randomization for SAD and 15 days for MAD
    • EditedArea under curve 0 to last quantifiable concentration (AUc o-LQC)Time frame: 24h and day 7 after randomization for SAD and 15 days for MAD → Auc0-lqc analyzed by plasma lvel at24h and day 7 after randomization for SAD and 15 days for MAD
    • EditedArea under curve over time during administration interval(A°UC 0-dai)|Time frame: 24h and day 7 after randomization for SAD and 15 days for MAD → Aucd0-sDAI analyzed by plasma lvel at24h and day 7 after randomization for SAD and 15 days for MAD
    • EditedArea under curve extrapolated(AUCextTime frame: 24h and day 7 after randomization for SAD and 15 days for MAD → Aucext analyzed by plasma lvel at24h and day 7 after randomization for SAD and 15 days for MAD
    • EditedPeak plasma concentration (ppc)Time frame: 24h and day 7 after randomization for SAD and 15 days for MAD → ppc tsken by plasma levels o RAP103 at24h and day 7 after randomization for SAD and 15 days for MAD
    • EditedConcentration at end of dosing range<<(cEDR9Time frame: 24h and day 7 after randomization for SAD and 15 days for MAD → cedr taken by plasma levels o RAP103 at24h and day 7 after randomization for SAD and 15 days for MAD
    • Time frameArea under the curve 0 to infinity24h and at day 7 post randomization for SAD and during 15 days for MAD → evaaluation o QRT intervlo by electrocardiogram24h and at day 7 post randomization for SAD and during 15 days for MAD

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07708831
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Sep 4, 2025
Primary completion
Feb 16, 2026
Completion
Apr 30, 2026
Last update
Oct 16, 2026

Study contacts

Juan MA Garcia Lara, MD, MSc
principal investigator · Innovación y Desarrollo en Ciencias de la Salud SRL de CV
Omar Cárdenas Sáenz, MD, MSc
principal investigator · Centro de Investigación Clínica y Medicina Translacional (CIMeT)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-0276

Start the discussion